FDA approves remdesivir for COVID-19
The antiviral drug reduces recovery time but has not been found to cut the risk of dying from COVID-19.
Watch CBS News
The antiviral drug reduces recovery time but has not been found to cut the risk of dying from COVID-19.
The U.S. government's deal to buy up most of the world's remdesivir has left many countries short, forcing families to pay up to 10 times the market price, if they can.
Daniel O'Day says the drug will soon be deployed to the "most urgent" patients following the drug's emergency use authorization Friday.
Daniel O'Day said on "Face the Nation" that Gilead has donated its entire supply of remdesivir to be administered to hospitalized COVID-19 patients.
The following is a transcript of an interview with Gilead Sciences CEO Daniel O'Day that aired Sunday, May 3, 2020, on "Face the Nation."
Hopes are high for antiviral drug after a clinical trial showed promise, but the benefits may be limited, experts say.
The antiviral drug remdesivir has shown promise in treating the COVID-19 infection in hospitalized patients. Dr. Mark McClellan, a professor of Business, Medicine and Policy at Duke University and a former FDA commissioner, joins CBSN's Reena Ninan for a closer look at the drug.
Gilead Sciences' remdesivir is farther along in testing than many other potential therapies and the studies could lead to regulatory approval.
A watchdog group is questioning whether drugmakers offer significant benefits in exchange for higher prices
The Canadian author says her sequel, "The Testaments," which continues the saga of the women of the dystopian society of Gilead, offers "tons of hope"
In her sequel to "The Handmaid's Tale," shortlisted for the Booker Prize, the author writes of attempts to wipe away the "corrupt and blood-smeared fingerprints of the past"
The actress and producer of the critically-acclaimed drama says the show's message is that women united are stronger and can affect change
Many retailers and health insurers have higher effective corporate tax rates than tech and pharmaceutical firms. Is that fair?
Drug costs for working-age Americans predicted to rise faster than next year's increases in wages or other costs of living
Regardless of the immediate uncertainty about the election, the U.S. economic fundamental backdrop looks very positive
New hepatitis C drug, Epclusa, carries a hefty price tag but has a high cure rate, research shows
Some of Corporate America's most tarnished names have turned up their charitable giving as part of rehab efforts
"Buy smart in May and make some hay" is a better approach, and these three stocks could fit that savvy strategy
Investors need a strategy for thriving in uncertain times, and these big-cap stocks could be part of the plan
Dr. Raymond Schinazi played a leading role developing a drug that cures hepatitis C while working seven-eighths of his time for the VA
Other countries pay far less for prescription meds than the U.S. -- blame lots of marketing and a lack of bargaining